Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1472

Sort by

Sort Order Select

Journal Articles

Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19)

Finn-Ole Paulsen, Christoph Schaefers, Florian Langer, Christian Frenzel, Ulrich Wenzel, Felicitas E. Hengel, Carsten Bokemeyer, Christoph Seidel

Blood (2021) 138 (11): 996–999.

https://doi.org/10.1182/blood.2021012790

Published: 2021

Includes: Supplemental data

Journal Articles

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Blood (2021) 138 (7): 571–583.

https://doi.org/10.1182/blood.2021010735

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Waleed Ghanima, Terry Gernsheimer, David J. Kuter

Blood (2021) 137 (20): 2736–2744.

https://doi.org/10.1182/blood.2021010968

Published: 2021

Journal Articles

Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition

Peter A. A. Norris, Gurleen Kaur, Ramsha Khan, Guangheng Zhu, Heyu Ni, Alan H. Lazarus

Blood (2021) 137 (15): 2114–2124.

https://doi.org/10.1182/blood.2020009497

Published: 2021

Includes: Supplemental data

Journal Articles

Anti-CD44 (Kur)lander hits ITP

Rick Kapur

Blood (2021) 137 (15): 1997–1999.

https://doi.org/10.1182/blood.2021011369

Published: 2021

Journal Articles

Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences

Taylor Olmsted Kim, Amanda B. Grimes, Susan E. Kirk, Megan M. Gilbert, Helen D. Reed, Kristen A. Staggers, Lauryn A. Walker, Abinaya Arulselvan, A. Sarah Cohen, Michele P. Lambert, Jenny M. Despotovic

Blood (2020) 136 (5): 640–643.

https://doi.org/10.1182/blood.2020004888

Published: 2020

Includes: Supplemental data

Journal Articles

Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP

Ramsha Khan, Melissa Menard, Chao-Ching Jen, Xi Chen, Peter A. A. Norris, Alan H. Lazarus

Blood (2020) 135 (26): 2420–2424.

https://doi.org/10.1182/blood.2019003646

Published: 2020

Includes: Supplemental data

Journal Articles

Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472-490.

Blood (2020) 135 (25): 2325.

https://doi.org/10.1182/blood.2020006529

Published: 2020

Journal Articles

Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment

Oriana Miltiadous, Ming Hou, James B. Bussel

Blood (2020) 135 (7): 472–490.

https://doi.org/10.1182/blood.2019003599

Published: 2020

Journal Articles

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Carlo Visco, Francesco Rodeghiero, Alessandra Romano, Federica Valeri, Michele Merli, Giulia Quaresimini, Stefano Volpetti, Roberto M. Santi, Giuseppe Carli, Elisa Lucchini, Francesco Passamonti, Alessandro Rambaldi, Giovanna Motta, Alessandra Borchiellini, Emanuele S. G. d’Amore, Marco Ruggeri

Blood (2019) 134 (20): 1708–1711.

https://doi.org/10.1182/blood.2019001617

Published: 2019

Includes: Supplemental data

Journal Articles

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Blood (2019) 134 (Supplement_1): 2361.

https://doi.org/10.1182/blood-2019-122237

Published: 2019

Journal Articles

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Alexandra Kruse, Caroline Kruse, Nancy Potthast, Kelsey Milligan, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 2362.

https://doi.org/10.1182/blood-2019-122278

Published: 2019

Journal Articles

No Increased Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

Margaux Lafaurie, PharmD, Bérangère Baricault, Vincent Soler, MD PhD, Myriam Cassagne, MD PhD, Laurent Sailler, MD PhD, Maryse Lapeyre-Mestre, MD PhD, Agnès Sommet, MD PhD, Guillaume Moulis, MD PhD

Blood (2019) 134 (Supplement_1): 2363.

https://doi.org/10.1182/blood-2019-124729

Published: 2019

Journal Articles

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

Anwar A. Sayed, MBBS, MSc, PhD, Amna Malik, PhD, Grace Ayoola, BSc., Elisa Lucchini, MD, Sasfia Candrianita, MD, Michelle H Tan, BSc, Camelia Vladescu, MSc, Deena Paul, Alice C J Hart, MBBS, BSc, MRCP, FRCPath(Haem), Ahmad Khoder, MD PhD MRCP, ASCP, Nesrina Imami, PhD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 2364.

https://doi.org/10.1182/blood-2019-122848

Published: 2019

Journal Articles

Is It Necessary to Combine Glucocorticoid in Newly Diagnosed ITP Infant Under 1 Year-Old with Severe Thrombocytopenia When Based on Intravenous Immunoglobulin Treatment ?

Shayi Jiang, MD, Eric S. Sandler, MD, Hui Jiang, PhD

Blood (2019) 134 (Supplement_1): 2368.

https://doi.org/10.1182/blood-2019-124827

Published: 2019

Journal Articles

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Kristin A. Shimano, MD, Rachael F. Grace, MD, Carolyn M. Bennett, MDMSc, Robert J Klaassen, MD FRCPC, Cindy Neunert, MD, Ellis J. Neufeld, MD, Clement Ma, PhD, Wendy B. London, PhD, Jenny M. Despotovic, DO, MS

Blood (2019) 134 (Supplement_1): 2369.

https://doi.org/10.1182/blood-2019-125487

Published: 2019

Journal Articles

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Blood (2019) 134 (Supplement_1): 2370.

https://doi.org/10.1182/blood-2019-125580

Published: 2019

Journal Articles

Elective Splenectomy in Immune Thrombocytopenic Purpura: An Analysis of National Inpatient Sample (NIS) Database between Years 2006 and 2014

Sunny R K Singh, MD, Sindhu Malapati, MD, Rohit Kumar, MD, Prasanth Lingamaneni, Leila Khaddour, MD, Vijayalakshmi Donthireddy

Blood (2019) 134 (Supplement_1): 4672.

https://doi.org/10.1182/blood-2019-127549

Published: 2019

Journal Articles

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Apoorva Krishna Chandar, MDMPH, Omar Ali Alaber, MD, Muhammad Zain Farooq, MD MBBS, Basma Ali Dahash, MD, Ankit Mangla, MBBS, MD

Blood (2019) 134 (Supplement_1): 4890.

https://doi.org/10.1182/blood-2019-127782

Published: 2019

Journal Articles

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Lamya Garabet, Pal André Holme, PhDMD, Bernadette Darne, Abderrahim Khelif, Tor Henrik Anderson Tvedt, MD, Marc Michel, Waleed Ghanima, MD PhD

Blood (2019) 134 (Supplement_1): 4892.

https://doi.org/10.1182/blood-2019-126974

Published: 2019

NARROW

Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19)

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition

Anti-CD44 (Kur)lander hits ITP

Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences

Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP

Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472-490.

Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

No Increased Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

Is It Necessary to Combine Glucocorticoid in Newly Diagnosed ITP Infant Under 1 Year-Old with Severe Thrombocytopenia When Based on Intravenous Immunoglobulin Treatment ?

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Elective Splenectomy in Immune Thrombocytopenic Purpura: An Analysis of National Inpatient Sample (NIS) Database between Years 2006 and 2014

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only